|Home | About TGA | Contact TGA | A-Z guide | Sitemap|
|Home > Reporting problems > Adverse drug reactions > Australian Adverse Drug Reactions Bulletin > November 1997|
Australian Adverse Drug Reactions Bulletin
Volume 16, Number 4, November 1997
Prepared by the ADVERSE DRUG REACTIONS ADVISORY COMMITTEE (ADRAC), a subcommittee of the Australian Drug Evaluation Committee. ADRAC is Dr Tim Mathew (Chair), Dr Ross Bradbury, Dr Paul Desmond, Dr Cecilie Lander, Professor Gillian Shenfield, Dr Dana Wainwright, Professor Lindon Wing.
SSRIs and neonatal disorders ......
The selective serotonin reuptake inhibitors (SSRIs) fluoxetine (Erocap, Lovan, Prozac, Zactin), fluvoxamine (Luvox), paroxetine (Aropax) and sertraline (Zoloft) are now the most widely used class of antidepressants in the Australian community. With this increasing use has come a relatively large number of reports to ADRAC (fluoxetine, 803; fluvoxamine, 5; paroxetine, 887; sertraline, 1243) including reports of effects on the neonate.
...... withdrawal reactions
Four reports to ADRAC describe withdrawal reactions in neonates whose mothers had taken SSRIs throughout their pregnancies. One case, in which the mother had taken fluoxetine, involved a three day old baby who developed tachypnoea, irritability, jitteriness, fever, anorexia, cyanosis and possible fitting. The second case, in which the mother had taken sertraline, concerned the smaller of a set of twins, who, at three days, became jittery and unsettled. The third case describes a baby who was treated for irritability and rapid breathing for two days after birth to a mother who had taken sertraline. The fourth case involved a mother who had taken fluoxetine and whose baby had a good Apgar score at birth but then became lethargic and fed poorly. The effects in all four cases appeared to resolve spontaneously.
...... breast milk transfer
A further four reports relate to probable breast milk transfer. In one report, a 5 month old breast fed baby whose mother was taking fluoxetine for post-partum depression, was found to have hyperglycaemia and glycosuria which resolved after the cessation of breast feeding. A second report describes a breast fed baby who became agitated, unsettled and had difficulty feeding while its mother was taking paroxetine. The outcome is unknown in this case. The third report describes a 5 month old baby who became agitated for a few days when her mother began taking sertraline for post-partum depression. This settled spontaneously while the mother continued with the drug. In the fourth report, a breast feeding mother took sertraline for about three months from the time her baby was 10 days old. During this time, the baby was somnolent, with low muscle tone, hearing problems and suspected developmental difficulties. When the mother discontinued the drug, the baby's condition improved dramatically and is now considered normal.
These reports suggest that adverse reactions to SSRIs can occur in neonates, through either placental or breast milk transfer. Practitioners should consider this possibility when prescribing to depressed patients who are pregnant or breastfeeding.
Prescribers may have noticed that during the past 2 years, a "boxed" safety warning has been included in the product information (PI) for a small number of drugs available on the Australian market. These drugs are associated with specific safety problems, whose clinical importance or severity are considered to have a critical impact on patient welfare. Special care should always be taken with a drug with a boxed warning. The content of the warning will be succinct and designed to draw the attention of the prescriber to information within the main body of the PI. The boxed warning will be applied in full to all advertisements and to brand name reminders in the form "see warning". A sample boxed warning appears below
Laboratory monitoring with calcitriol - an update
In the February Bulletin, ADRAC drew attention to the problem of hypercalcaemia in association with calcitriol (Rocaltrol).1 In that article, it was pointed out that the product information for calcitriol had a precaution concerning serum calcium monitoring. This involved twice weekly determinations of serum calcium early in therapy with at least weekly determinations for the first 12 weeks and monthly determinations thereafter. The product information has now been changed so that laboratory monitoring is specified according to the indication for use. For osteoporosis, the indication for which ADRAC has received most reports, the current recommendation for serum calcium monitoring is as follows:
Fatal outcomes after sumatriptan
In 1993, ADRAC drew attention to the problem of chest pain associated with the use of sumatriptan. Subsequently, ADRAC has received 3 reports documenting a fatal outcome.
Although there were significant confounding features, these 3 reports describe fatal outcomes following the onset of chest pain in women who had taken sumatriptan orally some hours earlier. None had complained of chest pain previously and in two cases there was evidence of myocardial ischaemia/infarction. The product information states that serious coronary events, hypotension and arrhythmias have been reported in connection with the use of sumatriptan. Prescribers should be aware that sumatriptan is contraindicated in any patient with heart disease or uncontrolled hypertension.
Please report all suspected reactions to these Drugs of Current Interest
What to report?
The Adverse Drug Reactions Advisory Committee (ADRAC) encourages the reporting of all suspected adverse reactions to drugs and other medicinal substances, including herbal, traditional or alternative remedies. The reporting of seemingly insignificant or common adverse reactions may highlight a widespread prescribing problem.
The Committee particularly requests reports of:
Reports of suspected adverse drug reactions are best made by using a prepaid reporting
form ("blue card") which is available from the Adverse Drug Reactions
Tear-out blue cards can also be found at the front of all recent editions of the "Schedule of Pharmaceutical Benefits".
Further information can be found from the medical and scientific staff in the ADRAC Secretariat:
(Problems with therapeutic devices should be reported on 1800-809361)
All correspondence to be addressed to: The Secretary, Adverse Drug Reactions Advisory Committee, PO Box 100, Woden ACT 2606